{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T17:19:00Z","timestamp":1766423940094,"version":"3.48.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"DOI":"10.7759\/cureus.99854","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T17:12:53Z","timestamp":1766423573000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Effectiveness: Impact of Cladribine on Patient-Reported Outcomes and Quality of Life in Latin American Populations With Multiple Sclerosis"],"prefix":"10.7759","author":[{"given":"Bernardita","family":"Soler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"C\u00e1rcamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"De La Barra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Trevi\u00f1o-Frenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Carra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricio","family":"Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Del Canto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Pelayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethel","family":"Ciampi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001136","article-title":"Epidemiology and pathophysiology of multiple sclerosis","volume":"28","author":"Ward M","year":"2022","unstructured":"Ward M, Goldman MD. Epidemiology and pathophysiology of multiple sclerosis. Continuum (Minneap Minn). 2022, 28:988-1005. 10.1212\/CON.0000000000001136","journal-title":"Continuum (Minneap Minn)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity","volume":"83","author":"Browne P","year":"2014","unstructured":"Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014, 83:1022-4. 10.1212\/WNL.0000000000000768","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251342855","article-title":"Cladribine tablets in the new multiple sclerosis era","volume":"18","author":"Buttari F","year":"2025","unstructured":"Buttari F, Dolcetti E, Rizzo FR, et al.. Cladribine tablets in the new multiple sclerosis era. Ther Adv Neurol Disord. 2025, 18:17562864251342855. 10.1177\/17562864251342855","journal-title":"Ther Adv Neurol Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines7010022","article-title":"Assessment and impact of cognitive impairment in multiple sclerosis: an overview","volume":"7","author":"Mac\u00edas Islas M\u00c1","year":"2019","unstructured":"Mac\u00edas Islas M\u00c1, Ciampi E. Assessment and impact of cognitive impairment in multiple sclerosis: an overview. Biomedicines. 2019, 7:22. 10.3390\/biomedicines7010022","journal-title":"Biomedicines"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.24.292359","article-title":"WHO model list of essential medicines: visions for the future","volume":"102","author":"Piggott T","year":"2024","unstructured":"Piggott T, Moja L, Huttner B, Okwen P, Raviglione MC, Kredo T, Sch\u00fcnemann HJ. WHO model list of essential medicines: visions for the future. Bull World Health Organ. 2024, 102:722-9. 10.2471\/BLT.24.292359","journal-title":"Bull World Health Organ"},{"key":"ref6","unstructured":"MINSAL. Tratamiento de segunda l\u00ednea basado en fingolimod o natalizumab o alemtuzumab o cladribina u ocrelizumab u ofatumumab para personas con esclerosis m\u00faltiple recurrente remitente con falla a tratamiento con inmunomoduladores y tratamiento con ocrelizumab para personas con esclerosis m\u00faltiple primaria progresiva. Ley Ricarte Soto N\u00ba20.850, Ministerio de Salud, Chile, Quinta Edici\u00f3n. (2024). Accessed: August 28, 2025: https:\/\/leyricartesoto.minsal.cl\/storage\/Qeso5K5LGmMClfUuBTA3h0T86Lf1JohxymlH4X9W.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara C","year":"2023","unstructured":"Oreja-Guevara C, Brownlee W, Celius EG, et al.. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence. Mult Scler Relat Disord. 2023, 69:104459. 10.1016\/j.msard.2022.104459","journal-title":"Mult Scler Relat Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni G","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, et al.. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018, 24:1594-604. 10.1177\/1352458517727603","journal-title":"Mult Scler"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni G","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al.. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010, 362:416-26. 10.1056\/NEJMoa0902533","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni G","year":"2023","unstructured":"Giovannoni G, Boyko A, Correale J, et al.. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY extension cohort of CLASSIC-MS: an ambispective study. Mult Scler. 2023, 29:719-30. 10.1177\/13524585231161494","journal-title":"Mult Scler"},{"key":"ref11","article-title":"Cladribine in the treatment of relapsing multiple sclerosis (Article in Spanish)","volume":"67","author":"Robles-Cedeno R","year":"2018","unstructured":"Robles-Cedeno R, Ramio-Torrenta L. Cladribine in the treatment of relapsing multiple sclerosis (Article in Spanish). Rev Neurol. 2018, 67:343-54.","journal-title":"Rev Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook S","year":"2019","unstructured":"Cook S, Leist T, Comi G, et al.. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019, 29:157-67. 10.1016\/j.msard.2018.11.021","journal-title":"Mult Scler Relat Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5603\/pjnns.101995","article-title":"Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy","volume":"59","author":"Ro\u015bciszewska-\u017bukowska I","year":"2025","unstructured":"Ro\u015bciszewska-\u017bukowska I, Ku\u0142akowska A, Kalinowska A, et al.. Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy. Neurol Neurochir Pol. 2025, 59:20-32. 10.5603\/pjnns.101995","journal-title":"Neurol Neurochir Pol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106272","article-title":"Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers","volume":"94","author":"Conway DS","year":"2025","unstructured":"Conway DS, Nicholas JA, Thompson NR, Mowry EM, Naismith RT. Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers. Mult Scler Relat Disord. 2025, 94:106272. 10.1016\/j.msard.2025.106272","journal-title":"Mult Scler Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104487","article-title":"Quality of life and mental health in multiple sclerosis patients during the COVID-19 pandemic","volume":"70","author":"Rodr\u00edguez-Agudelo Y","year":"2023","unstructured":"Rodr\u00edguez-Agudelo Y, Nava-Ad\u00e1n J, Paz-Rodr\u00edguez F, Abundes-Corona A, Flores-Rivera J, Corona T. Quality of life and mental health in multiple sclerosis patients during the COVID-19 pandemic. Mult Scler Relat Disord. 2023, 70:104487. 10.1016\/j.msard.2022.104487","journal-title":"Mult Scler Relat Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke JF","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33:1444-52. 10.1212\/wnl.33.11.1444","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin FD","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, et al.. How patients with multiple sclerosis acquire disability. Brain. 2022, 145:3147-61. 10.1093\/brain\/awac016","journal-title":"Brain"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15406","article-title":"Confirmed disability progression as a marker of permanent disability in multiple sclerosis","volume":"29","author":"Sharmin S","year":"2022","unstructured":"Sharmin S, Bovis F, Malpas C, et al.. Confirmed disability progression as a marker of permanent disability in multiple sclerosis. Eur J Neurol. 2022, 29:2321-34. 10.1111\/ene.15406","journal-title":"Eur J Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","volume":"15","author":"Filippi M","year":"2016","unstructured":"Filippi M, Rocca MA, Ciccarelli O, et al.. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016, 15:292-303. 10.1016\/S1474-4422(15)00393-2","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001059","article-title":"Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis","volume":"8","author":"Prosperini L","year":"2021","unstructured":"Prosperini L, Ruggieri S, Haggiag S, Tortorella C, Pozzilli C, Gasperini C. Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021, 8:e1059. 10.1212\/NXI.0000000000001059","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211010294","article-title":"Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY extension studies","volume":"28","author":"De Stefano N","year":"2022","unstructured":"De Stefano N, Sormani MP, Giovannoni G, et al.. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY extension studies. Mult Scler. 2022, 28:111-20. 10.1177\/13524585211010294","journal-title":"Mult Scler"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-55","article-title":"Brief International Cognitive Assessment for MS (BICAMS): international standards for validation","volume":"12","author":"Benedict RH","year":"2012","unstructured":"Benedict RH, Amato MP, Boringa J, et al.. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol. 2012, 12:55. 10.1186\/1471-2377-12-55","journal-title":"BMC Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.5.871","article-title":"Development of a multiple sclerosis functional composite as a clinical trial outcome measure","volume":"122","author":"Cutter GR","year":"1999","unstructured":"Cutter GR, Baier ML, Rudick RA, et al.. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999, 122:871-82. 10.1093\/brain\/122.5.871","journal-title":"Brain"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20130588","article-title":"Associations of upper limb disability measures on different levels of the International Classification of Functioning, Disability and Health in people with multiple sclerosis","volume":"95","author":"Lamers I","year":"2015","unstructured":"Lamers I, Cattaneo D, Chen CC, Bertoni R, Van Wijmeersch B, Feys P. Associations of upper limb disability measures on different levels of the International Classification of Functioning, Disability and Health in people with multiple sclerosis. Phys Ther. 2015, 95:65-75. 10.2522\/ptj.20130588","journal-title":"Phys Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.54.4.802","article-title":"Intrarater and interrater reliability of the MS functional composite outcome measure","volume":"54","author":"Cohen JA","year":"2000","unstructured":"Cohen JA, Fischer JS, Bolibrush DM, et al.. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology. 2000, 54:802-6. 10.1212\/wnl.54.4.802","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/135245850000600411","article-title":"The significant change for the timed 25-foot walk in the multiple sclerosis functional composite","volume":"6","author":"Kaufman M","year":"2000","unstructured":"Kaufman M, Moyer D, Norton J. The significant change for the timed 25-foot walk in the multiple sclerosis functional composite. Mult Scler. 2000, 6:286-90. 10.1177\/135245850000600411","journal-title":"Mult Scler"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart J","year":"2001","unstructured":"Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001, 124:962-73. 10.1093\/brain\/124.5.962","journal-title":"Brain"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck AT","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961, 4:561-71. 10.1001\/archpsyc.1961.01710120031004","journal-title":"Arch Gen Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1037\/\/0022-006x.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck AT","year":"1988","unstructured":"Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988, 56:893-7. 10.1037\/\/0022-006x.56.6.893","journal-title":"J Consult Clin Psychol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.05.023","article-title":"Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale","volume":"331","author":"Learmonth YC","year":"2013","unstructured":"Learmonth YC, Dlugonski D, Pilutti LA, Sandroff BM, Klaren R, Motl RW. Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale. J Neurol Sci. 2013, 331:102-7. 10.1016\/j.jns.2013.05.023","journal-title":"J Neurol Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12932","article-title":"Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis","volume":"23","author":"Sacco R","year":"2016","unstructured":"Sacco R, Santangelo G, Stamenova S, et al.. Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis. Eur J Neurol. 2016, 23:744-50. 10.1111\/ene.12932","journal-title":"Eur J Neurol"},{"key":"ref32","article-title":"Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests","volume":"69","author":"Goodkin DE","year":"1988","unstructured":"Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil. 1988, 69:850-4.","journal-title":"Arch Phys Med Rehabil"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510370464","article-title":"Progression on the multiple sclerosis functional composite in multiple sclerosis: what is the optimal cut-off for the three components?","volume":"16","author":"Bosma LV","year":"2010","unstructured":"Bosma LV, Kragt JJ, Brieva L, et al.. Progression on the multiple sclerosis functional composite in multiple sclerosis: what is the optimal cut-off for the three components?. Mult Scler. 2010, 16:862-7. 10.1177\/1352458510370464","journal-title":"Mult Scler"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516680749","article-title":"Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale","volume":"23","author":"Goldman MD","year":"2017","unstructured":"Goldman MD, Ward MD, Motl RW, Jones DE, Pula JH, Cadavid D. Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. Mult Scler. 2017, 23:1405-14. 10.1177\/1352458516680749","journal-title":"Mult Scler"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231205962","article-title":"Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: the CLARIFY-MS study","volume":"29","author":"Brochet B","year":"2023","unstructured":"Brochet B, Solari A, Lechner-Scott J, et al.. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: the CLARIFY-MS study. Mult Scler. 2023, 29:1808-18. 10.1177\/13524585231205962","journal-title":"Mult Scler"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517726380","article-title":"Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis","volume":"24","author":"Afolabi D","year":"2018","unstructured":"Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler. 2018, 24:1461-8. 10.1177\/1352458517726380","journal-title":"Mult Scler"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/412836-beyond-effectiveness-impact-of-cladribine-on-patient-reported-outcomes-and-quality-of-life-in-latin-american-populations-with-multiple-sclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T17:12:54Z","timestamp":1766423574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/412836-beyond-effectiveness-impact-of-cladribine-on-patient-reported-outcomes-and-quality-of-life-in-latin-american-populations-with-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.99854","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}